STAAR Surgical Announces EVO ICL Clinical Program for Its 16th Annual Surgical Experts Summit in Paris, France From September...
September 09 2019 - 6:00AM
Business Wire
STAAR Surgical Company (NASDAQ: STAA), a leading developer,
manufacturer and marketer of implantable lenses and companion
delivery systems for the eye, is today announcing the EVO ICL
Clinical Program which will be presented by Ophthalmic Surgeons to
Ophthalmic Surgeons at its invitation only Surgical Experts Summit.
The Summit is expected to be attended by over 250 surgeons and
invited clinician guests from forty-six countries. The Experts
Summit will be held in Paris, France, directly ahead of the
European Society of Cataract and Refractive Surgeons Meeting
(ESCRS). Thirty-one surgeons will present clinical data and
moderate presentations, panels and roundtable sessions on the EVO
Visian ICL and Refractive Surgery topics of essential interest. The
following is a representative selection from the myriad clinical
topics to be addressed during the Experts Summit:
- My Paradigm Shifts in Refractive Surgery: Why I moved to an ICL
Only Practice
- EVO Visian ICL for Myopes over 45 Years: Clinical Outcomes
- Immediate Bilateral EVO Surgery Protocol
- Improving Optics in Challenging Corneas
- Best Screening for Keratoconus & EVO Visian ICL
Application
- EVO Visian ICL and SMILE in Low-to-Moderate Diopter
Patient
- Over 20 years of EVO Visian ICL in My Patient’s Eyes
- Key Clinical Drivers for EVO Visian ICL Indications
- Developing a Consensus Group Approach in China - Relevance and
Future Outlook.
Following the Experts Summit, STAAR will exhibit at the ESCRS in
Paris at Pavilion 7, Paris Expo Porto de Versailles, Booth Number
E101 from Saturday, September 14th, through Wednesday, September
18th. STAAR will host Pre-Certification Surgeon Training Courses,
Roundtables and Education Sessions including Digital Marketing and
Patient Education tutorials. At this time, STAAR is expecting over
50 talks at the Congress where STAAR is presented alone or in
combination with other refractive surgical options. “Our Experts
Summit and ESCRS are among our largest and most important customer
events each year. We wish to thank in advance all the global
refractive surgeon experts who are dedicated to making the ICL the
premium and primary refractive procedure for vision correction,”
said Caren Mason, President & CEO of STAAR Surgical.
About STAAR Surgical
STAAR, which has been dedicated solely to ophthalmic surgery for
over 30 years, designs, develops, manufactures and markets
implantable lenses for the eye with companion delivery systems.
These lenses are intended to provide visual freedom for patients,
lessening or eliminating the reliance on glasses or contact lenses.
All of these lenses are foldable, which permits the surgeon to
insert them through a small incision. STAAR’s lens used in
refractive surgery is called an Implantable Collamer® Lens or
“ICL”, which includes the EVO Visian ICL™ product line. More than
1,000,000 Visian® ICLs have been implanted to date and STAAR
markets these lenses in over 75 countries. To learn more about the
ICL go to: www.discovericl.com. Headquartered in Lake Forest, CA,
the company operates manufacturing and packaging facilities in
Aliso Viejo, CA, Monrovia, CA and Nidau, Switzerland. For more
information, please visit the Company’s website at
www.staar.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190909005230/en/
Investors & Media Brian Moore Sr. Director, Investor,
Media Relations and Corporate Development (626) 303-7902, Ext. 3023
bmoore@staar.com
STAAR Surgical (NASDAQ:STAA)
Historical Stock Chart
From Apr 2024 to May 2024
STAAR Surgical (NASDAQ:STAA)
Historical Stock Chart
From May 2023 to May 2024